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Despite the generalized use of photon-based radiation (i.e., gamma rays and X-rays) 
to treat different cancer types, particle radiotherapy (i.e., protons and carbon ions) is 
becoming a popular, and more effective tool to treat specific tumors due to the improved 
physical properties and biological effectiveness. Current scientific evidence indicates 
that conventional radiation therapy affects the tumor immunological profile in a particular 
manner, which in turn, might induce beneficial effects both at local and systemic (i.e., 
abscopal effects) levels. The interaction between radiotherapy and the immune system is 
being explored to combine immune and radiation (including particles) treatments, which 
in many cases have a greater clinical effect than any of the therapies alone. Contrary 
to localized, clinical irradiation, astronauts are exposed to whole body, chronic cosmic 
radiation, where protons and heavy ions are an important component. The effects of this 
extreme environment during long periods of time, e.g., a potential mission to Mars, will 
have an impact on the immune system that could jeopardize the health of the astronauts, 
hence the success of the mission. To this background, the purpose of this mini review 
is to briefly present the current knowledge in local and systemic immune alterations 
triggered by particle irradiation and to propose new lines of future research. Immune 
effects induced by particle radiation relevant to clinical applications will be covered, 
together with examples of combined radiotherapy and immunotherapy. Then, the focus 
will move to outer space, where the immune system alterations induced by cosmic 
radiation during spaceflight will be discussed.
Keywords: protons, carbon ions, immunotherapy, space flight, cosmic radiation, immune response, cancer 
therapy
inTRODUCTiOn
The main purpose of radiotherapy is to induce DNA damage in tumor cells to trigger a network of 
events leading to cell death. However, conventional photon radiotherapy can also modify the tumor 
phenotype and its environment, making the tumor more vulnerable to the immune system. Some 
examples are the increased expression of major histocompatibility complex I in tumor cells (1) and 
the modulation of in situ secretion of cytokines (2). In addition to local alterations, it is now obvious 
that the effect of radiation goes beyond the cells directly affected by the irradiation source, leading to 
non-targeted effects. Indeed, several studies have shown that radiation exposure is harmful for non-
irradiated cells (3, 4). However, it is also clear that non-targeted radiation effects can lead to abscopal 
TABLe 1 | Radiation characteristics of particle therapy and cosmic radiation and effects on the immune system.
Particle therapy Cosmic radiation
Target tissue Very localized → tumor Whole body, healthy tissue
Exposure Several sessions (fractionation) Chronic
Source Particle accelerators Galaxy, the Sun
Particle type Protons or heavy ions such as C (also H, Li, O, etc.) Protons, H ions, HZE particles (e.g., Fe), and electrons
Maximal energy ~200 MeV for protons and ~600 MeV for C ions ~1,000 MeV for protons and ~600 MeV for heavy ions
Dose Target tissue: high – 60–80 Gy-eq ~662 mSv (in a round trip to Mars, without considering 
the time spent in the planet)
Secondary irradiation Problem of neutrons leakage Secondary cosmic rays due to vehicle shielding
Short-term immune effects Alterations in tumor cells and their environment leading to 
immunogenic cell death
aSignificant downregulation of different components of 
the immune system [more affected—B cell > T cells 
(CD8+ > CD4+) > NK cells—less affected]
Long-term immune effects Systemic immunogenic response affecting specific tumor cells 
both local and distant (abscopal effects)
aMainly unknown. Immune system downregulated 
response may persist
Potential outcome Improve survival of cancer patients Immune dysregulation → major health risk for astronauts 
during exploratory missions
H, hydrogen; C, carbon; Li, lithium; O, oxygen; Fe, iron; NK, natural killer.
aFrom animal studies.
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effects, i.e., an uncommon event of tumor regression at a site or 
tissue distant from the primary site of radiation (5). Case reports 
showing remission of metastatic events in specific conditions 
are believed to be the result of abscopal effects (6–8). Although 
the information regarding the driving machinery controlling 
these abscopal effects is not totally understood, the immune 
system plays a key role (9–11). This information highlights the 
importance of antitumor immunity development after radiation 
therapy, and the potential added benefits of combined radio-
therapy and immunotherapy.
Most of the data about radiation-induced immune alterations 
are based on research employing photon-based sources (i.e., 
gamma rays and X-rays). Although conventional radiation is 
the most popular tool used in clinical settings, antitumor treat-
ments using particle irradiation (i.e., protons or carbon ions) are 
becoming a useful alternative. Indeed, the number of facilities 
allowing for particle therapy is growing at a high rate in the last 
decade.1 From a physical perspective, the inverted depth-dose 
profile and the sharp dose fall-off after the Bragg peak offered by 
particle beams allow for a more precise localization of the radia-
tion dosage to the tumor, as compared to conventional photons 
(12). Besides the ballistic advantage, the use of high-linear energy 
transfer (LET) carbon ion beams offers a biological advantage as 
well, i.e., a higher relative biological effectiveness (RBE) compared 
to photon and proton exposure (13). However, recent studies 
suggest that both protons and carbon ions have unique biological 
properties when compared with photons (14, 15). Considering 
these physical and biological characteristics, different radiation 
types could induce divergent immune alterations, which will in 
turn determine the type and magnitude of local and systemic 
(abscopal) immune effects.
Contrary to local irradiation for tumor treatment, there 
are some particular situations where the entire human body is 
1 https://www.ptcog.ch/.
subjected to particle irradiation, such as human space flight. In 
this case, healthy tissue will be chronically exposed to energetic 
radiation, inducing different effects on the immune system (for a 
comparison, see Table 1). Although the immune alterations dur-
ing space flight are mainly a result of microgravity, psychological 
stress, and radiation (16), it is believed that radiation per se will 
be a major determinant of astronauts’ immune system status in 
long-term, exploratory-type missions. Supporting this hypoth-
esis, there are several animal studies showing how simulated 
cosmic radiation clearly interferes with the immune system (see 
below).
The purpose of this mini review is to briefly present the current 
knowledge in immune alterations triggered by particle irradia-
tion and to propose new lines of future research. In particular, 
immune effects induced by particle radiotherapy (protons and 
carbon ions) will be covered, together with promising examples 
of combined particle therapy and immunotherapy. Then, we 
will focus on a very specific situation where healthy humans are 
subjected to this type of radiation (i.e., space flights), and how 
such environment might affect their immune system.
PARTiCLe THeRAPY
Radiotherapy is used for local tumor control through radiation-
induced killing of cancer cells. Nowadays, it is accepted that 
the success of radiotherapy also involves the immune system. 
The radiation-induced tumor cell death enables the presenta-
tion of tumor-derived antigens by dendritic cells (DCs). These 
antigen-presenting cells function as a bridge between the innate 
and adaptive immunity (17), thereby leading to the induction of 
tumor-specific cytotoxic T cells (18–20).This can result in the 
initiation of local and systemic antitumor immune responses 
(10). In this regard, adequate combination of radiotherapy and 
immunotherapy has opened new possibilities to treat metastatic 
and advanced cases. Common immunotherapeutic strategies 
combined with radiation include administration of cancer-specific 
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antibodies, cytokines, cancer vaccines, and immune checkpoint 
inhibitors (21).
Besides conventional radiotherapy, particle therapy with 
protons or carbon ions has become the treatment of choice for 
specific cancer types. Due to the improved dose distribution, 
particle irradiation enhances local tumor control. In addition, 
both proton and carbon ions show unique molecular and cellular 
responses compared to photon radiation (14, 15, 22).
Preclinical Studies
Conventional radiotherapy increases the expression of specific 
surface molecules, adhesion molecules, death receptors, stress-
induced ligands, and classical stimulatory molecules, leading to 
increased immunogenicity (23). However, only a limited num-
ber of preclinical in  vitro and in  vivo studies have investigated 
whether particle radiation can modify tumor cells into a more 
immunogenic phenotype, increasing their sensitivity to immune 
surveillance.
Proton irradiation modulates several processes critical in 
tumor advancement and progression, including angiogenesis and 
immunogenicity. Indeed, decreased levels of vascular endothelial 
growth factor, interleukin (IL)-6, IL-8, and hypoxia-inducible 
factor 1-alpha, have been reported in lung carcinoma cells after 
proton exposure (14, 22). A recent study reported how sublethal 
proton or photon irradiation induced a similar increase in the 
levels of surface molecules involved in T-cell recognition, as well 
as translocation of calreticulin to the tumor cell surface (24). 
The latter is critical for increased sensitivity to T cell killing (25). 
These changes in the immunogenic phenotype in a wide array of 
cancer cell types after proton exposure can make malignant cells 
more sensitive to T-cell-mediated cell death. In addition, proton 
therapy induced a downregulation of PD-L1 in prostate tumor 
cells, potentially leading to a higher T-cell activity in irradiated 
tumors (24).
Our group has shown that carbon ion irradiation induces 
changes in the expression of genes involved in tumor progression 
in human prostate cancer cells (26). Genes involved in cell migra-
tion and motility were expressed in a dose- and time-dependent 
manner (27). Recently, the immunogenic alterations induced 
by carbon ion irradiation were investigated in another human 
in vitro model (28). Carbon ion radiation increased the levels of 
high mobility group box 1 (HMGB1) in the culture supernatants 
of different human cancer cell lines. HMGB1 plays an important 
role in antigen-presenting cell activation and induction of an effi-
cient immune response (10, 29). The levels of HMGB1 induced 
by carbon ion exposure were comparable with iso-survival doses 
of X-rays, and the applied doses were similar to those used in the 
clinic.
Surprisingly, although the number of patients treated with 
protons far exceeds that of carbon ion-treated patients, preclinical 
studies with particles have focused on the impact of carbon ion 
irradiation on the antitumor immunity. Preclinical in vivo studies 
using carbon ion radiation have convincingly demonstrated that 
carbon ion exposure induces antitumor immunity in immuno-
competent animals, together with abscopal effects in some cases. 
When compared with photon irradiation, carbon ion exposure 
reduced the number of distant lung metastasis in carcinoma 
models in immunocompetent mice (30) and induced a higher 
expression of membrane-associated immunogenic molecules in 
mice tumors (31). The latter may highlight the superior potential 
of particle therapy vs. photons to be combined with immuno-
therapy. On the contrary, no greater benefits of carbon ions 
compared with photons were observed in a pulmonary metastatic 
murine model (32).
To our knowledge, only two preclinical studies combining 
carbon ion radiation and immunotherapy have been published 
(33, 34). In both cases, carbon ion irradiation was combined with 
the administration of bone marrow DCs in immunocompetent 
mice. Although carbon ion exposure alone had enough potential 
to activate DCs (33), greater antitumor immunity and a reduc-
tion in the number of metastasis were reported after combined 
radiotherapy and immunotherapy (33, 34). Interestingly, the 
combination of DC immunotherapy and photon radiation was 
not able to induce the same effects (35). These results suggest 
that even when exposed to the same equivalent doses, carbon 
ion therapy might activate the immune system to a greater extent 
than conventional radiotherapy.
Case Reports and Clinical Trials: immune-
Activating Properties of Radiotherapy
Abscopal responses after particle therapy have been occasion-
ally reported in patients treated in Japan. A patient with colon 
carcinoma and distant lymph node metastasis was treated with 
local carbon ion therapy. Six months after treatment, both the 
primary tumor and the metastasis resolved (36). Abscopal regres-
sion was also described in a patient who had both abdominal and 
para-aortic lymph node metastases. He was treated with different 
fractions of carbon ion irradiation for the abdominal lymph 
nodes only. After 6 months, both metastases were reduced (37).
With the increase in knowledge about the combination of 
particle radiotherapy and immunotherapy, novel clinical trials 
employing particle therapy with adjuvant systemic immuno-
therapy must be performed. Indeed, several clinical trials inves-
tigating such combination of therapies are currently ongoing,2 
and some have already been completed. The combination of 
intratumoral injection of hydroxyapatite as immune adjuvant 
and proton beam therapy was found to be feasible and safe in 
patients with locally advanced or recurrent hepatocellular carci-
noma (phase I study) (38). Four of nine patients were progression 
free for >1 year.
Open Questions
Dose and fractionation are likely to be key variables in determin-
ing the effects of ionizing radiation on the immune system of 
the patients and/or in determining the success of radiotherapy 
when combined with different forms of immunotherapy. Indeed, 
modifying the fractionation protocol can have a major impact 
on, e.g., DCs, activation (39). In the context of particle therapy, 
enhanced immune reactions may be involved in response to 
hypofractionation, where patients receive a higher single dose 
in a lower number of fractions (37). Until now, data describing 
2 https://clinicaltrials.gov/.
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the immunogenicity in response to particle therapy are mostly 
based on single high-radiation doses, which are not commonly 
used in clinical settings. In addition, when analyzing combined 
approaches, the correct sequencing of radiation may depend on 
the type of immunotherapy chosen. Therefore, there is an urgent 
need to test and further identify the immunogenic properties of 
different fractionation schemes, and how such schemes should 
be combined with immunotherapy to boost beneficial adapta-
tions. In addition, proton treatment is now based on a generic 
RBE value of 1.1. However, when treating a tumor volume, the 
RBE is increasing in the distal end of the spread-out Bragg peak 
(40). Research is needed to investigate whether different RBEs of 
protons affect the immunogenicity in different parts of the tumor.
SPACe RADiATiOn
Cosmic radiation is composed of galactic cosmic rays (GCRs) 
and solar particle events (SPEs) (41). GCRs are the continuous, 
background radiation that any mission beyond the magnetic 
field of the Earth will encounter. Protons are the main compo-
nent of the GCRs, making up to 85% of the total. About 11–14% 
of the GCRs flux is helium ions, and ~2% consist of electrons. 
Importantly, there is a small, still very significant 1% of high (H) 
atomic number (Z) and high-energy (E) particles (HZE particles). 
Among them, Iron is the most important one due to its high LET. 
In addition to the GCRs, astronauts undergoing interplanetary 
missions will have to face the unpredictable SPEs containing 
energetic particles (mainly protons) from the Sun. Of note, the 
shielding used in the spaceship can interact with particles from 
GCRs and SPEs creating secondary radiation, which can increase 
the effectiveness of irradiation by heavy ions (42). All in all, the 
most accurate estimations indicate that the radiation levels for 
the shortest round-trip to Mars would be in the order of >0.6 Sv 
(43), which is close to, or even above, the dose limits proposed by 
NASA for the entire career of an astronaut (44). Indeed, radiation 
is one of the major concerns to maintain astronauts’ health during 
exploratory-type missions.
The adverse effect of cosmic radiation on the immune system is 
a matter of concern, given that some components of the immune 
system are among the most radiation-sensitive tissues in the body 
(41). A good example is the chromosomal aberrations described 
after missions in low-Earth orbit [e.g., Ref. (45–49)], where the 
dose is much lower than that expected during a trip to Mars. 
When exposed to simulated cosmic radiation with or without 
shielding, in vitro human lymphocytes also show chromosomal 
damage, which is dependent on the radiation quality, and the type 
of shielding (50, 51).
Despite investigations performed in low-Earth-orbit, there is 
a lack of data analyzing the effects of cosmic radiation beyond 
Earth’s magnetic fields on the human immune system. Indeed, 
only a few humans have gone far enough to experience the full 
spectrum of cosmic radiation (NASA Apollo missions). Hence, 
the most appropriate approach we currently have to study cosmic 
radiation-induced effects on the immune system are animal mod-
els. The research team of Drs. Griedly and Pecaut has performed 
multiple ground-based experiments with murine models to ana-
lyze the immune system response to simulated GCRs and SPEs. 
These investigations have shown that simulated cosmic radiation 
decreases the lymphocyte population (52), with a higher impact 
on B cells, followed by T cells (CD8+ > CD4+) and natural killer 
cells (53–55). The response and function of leukocytes are also 
altered by simulated cosmic radiation (55), and the effects are 
long lasting and dependent on the dose, the type of source, and 
the body compartment (56–59). Overall, these results are sup-
ported by investigations from other groups (60, 61).
A matter of debate regarding cosmic radiation is whether 
previous radiation exposure can make humans more radioresist-
ant. Pre-exposure to low-dose photon radiation may decrease the 
regeneration capacity of lymphocytes after simulated SPE radia-
tion (62). Contrarily, previous exposure to low-dose radiation 
may offer some degree of radioprotection to reduce expansion 
of T regulatory cells (Treg; immunosupressive cells involved in 
tumor development) in response to subsequent proton (e.g., SPE) 
irradiation (63). This is important given that the proportion of Treg 
cells is increased after simulated SPE radiation (62). Despite the 
controversy about potential radioprotection from pre-exposure 
with low-dose radiation to SPEs or GCRs at the cell pupulation 
level, it seems clear that such priming technique modifies the 
molecular signaling of immune cells in mice (64, 65).
Open Questions
In addition to the uncertainties and difficulties to study the 
immune system alterations to space radiation, it should be 
noted that radiation is not the only “space stressor” affecting the 
immune system. Confinement, circadian rhythms, psychological 
stress, and microgravity may add (or counteract) the effects of 
radiation in the immune system of astronauts (16). To study 
the combined effects of multiple space stressors, in vitro models 
should provide a valuable platform (66). Indeed, controversy 
exists about whether microgravity increases human immune 
system radiosensitivity in space, by, e.g., increasing cell apoptosis 
after heavy ion exposure (67, 68) or not (69). In addition, better 
models and platforms allowing investigations using human liv-
ing tissues and space-like radiation should be developed. Finally, 
an interesting and ongoing topic of research valuable for future 
long-term space missions is the development of tools to identify 
the subjects that are more resistant to space radiation.
COnCLUDinG ReMARKS
From a physical point of view, the rationale for the use of particle 
irradiation in cancer therapy has been obvious for a very long 
time. Adding to this, recent studies have shown that particle 
therapy may exert interesting effects on tumor cells that might 
eventually increase the effectiveness of the antitumor immune 
response.
Surprisingly, there is a lack of preclinical in  vivo data com-
bining proton therapy and immunotherapy, and the number of 
preclinical studies with carbon ions is very limited. This topic 
warrants further investigation to exploit this strategy to kill can-
cer cells that are outside the primary radiation field. Promising 
approaches include the combination of particle therapy with 
immune system modulators, immune checkpoint inhibitors, and 
cytokines.
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Besides clinical studies, basic research should investigate 
underlying immune mechanisms leading to an efficient antitu-
mor response. This research may translate into new, more effec-
tive therapeutic approaches. Moreover, differences in individual 
radiosensitivity, which may influence non-targeted, abscopal 
radiation responses, should be further examined.
Individual radiosensitivity should also be analyzed in the 
context of human spaceflight and immune system alterations, 
together with the potential beneficial effects of pre-exposure to 
low-dose radiation before spaceflight. Given that cosmic radia-
tion clearly downregulates the immune system, such information 
could help selecting the most appropriate individuals to succeed 
in a long-term, exploratory mission.
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